Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Day One Biopharmaceuticals filings document the company's transition from a Nasdaq-listed oncology biopharmaceutical issuer to an acquired company with Exchange Act deregistration filings. The record includes Form 25 removal of DAWN common stock from Nasdaq and Form 15 certification covering termination of registration or suspension of reporting duties after the acquisition.
Day One's 8-K filings report material agreements, tender-offer and merger-related events, shareholder voting and governance matters, capital-structure disclosures, and financial-statement exhibits. Other disclosures cover OJEMDA (tovorafenib), U.S. product revenue reporting, Ipsen's ex-U.S. commercialization rights, and clinical or regulatory updates for pediatric low-grade glioma and rare-cancer programs.
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics via a two‑step deal starting with a tender offer for all shares at $25.00 in cash per share plus one CVR worth up to an additional $30.25 per share upon specified milestones. The offer will be open for 20 business days, followed by a back‑end merger under DGCL 251(h) without a stockholder vote once the tender closes.
Closing is targeted by the end of January 2026, subject to customary conditions, including HSR clearance and a 50%+1 share minimum tender. The transaction has no financing condition. Support agreements from directors, officers and Bain Capital–affiliated holders cover about 8.5% of Mersana’s shares. Either party may terminate if not consummated by May 12, 2026; certain terminations require Mersana to pay a $5.6 million fee. CVRs are non‑transferable contractual rights with cash payouts only if milestones are achieved.
Day One Biopharmaceuticals (DAWN): Director Form 4 discloses option repricing. On 11/06/2025, two stock option grants were repriced to an exercise price of $8.99, equal to the Nasdaq closing price on the effective date if lower than the original price.
The actions replaced options for 66,660 shares at $13.81 and 32,335 shares at $13.87 with new options at $8.99. To exercise the repriced options, the reporting person must remain in service through the Retention Period, ending on the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction. One grant vests 1/36 monthly beginning 02/17/2024; the other is fully vested.
Day One Biopharmaceuticals (DAWN) reported a Form 4 showing an option repricing for its Chief Executive Officer effective November 6, 2025, following Board approval on October 7, 2025. The affected stock options were reset to a new exercise price of $8.99, the Nasdaq closing price on the effective date, with no change to other terms.
Affected grants include options previously priced at $16.00 (covering 1,463,134 shares), $14.26 (397,000 shares), $23.41 (244,000 shares), and $14.44 (286,000 shares). One grant is fully vested; others vest monthly per their original schedules.
Exercising the repriced options at $8.99 requires the CEO to remain in service through the defined Retention Period, which ends on the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction. The transactions were reported as exempt under Rule 16b‑6(d) and Rule 16b‑3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 showing an option repricing for a director. On 11/06/2025, fully vested stock options were repriced to an exercise price of $8.99, replacing prior grants with higher strike prices while keeping original terms and expirations. The transactions include exchanges of 63,000 (from $16; expiring 05/25/2031), 1,181 (from $16; 05/25/2031), 28,700 (from $16.29; 06/20/2032), 37,500 (from $12.69; 06/21/2033), and 32,335 (from $13.87; 05/22/2034) options, each reacquired at $8.99. The board approved the repricing on 10/07/2025. Exercising at the new price requires service through a “Retention Period” that ends on the earliest of the 12‑month anniversary of the effective date or a Corporate Transaction; other terms remain unchanged.
Day One Biopharmaceuticals (DAWN) disclosed a director’s option repricing on a Form 4. The Board approved the action on October 7, 2025, and it became effective on November 6, 2025. Previously granted stock options with exercise prices of $16.00, $16.29, $12.69, and $13.87 were disposed and replaced with options at a new exercise price of $8.99.
The repriced grants cover 40,000, 40,300, 28,700, 37,500, and 32,335 underlying shares, respectively, and are reported as directly owned. The options are fully vested. To exercise at the new price, the reporting person must remain in service through the “Retention Period,” which ends at the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction; the footnotes note an exception related to death or Disability under the company’s 2021 Equity Incentive Plan. The transactions were exempt under Rules 16b‑6(d) and 16b‑3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 reporting an option repricing for a director. On 11/06/2025, previously granted stock options with exercise prices of $25.84 (33,900 shares), $12.69 (37,500 shares), and $13.87 (32,335 shares) were replaced with options at a new exercise price of $8.99, matching the Nasdaq closing price on the effective date. The Board approved the repricing on 10/07/2025.
The options are fully vested. To exercise at the new price, the reporting person must remain in service through the “Retention Period,” which ends at the earlier of the 12-month anniversary of 11/06/2025 or a Corporate Transaction, with certain exceptions for death or Disability as defined in the company’s 2021 plan.
Day One Biopharmaceuticals (DAWN) director filed a Form 4 reporting an option repricing approved on Oct 7, 2025 and effective Nov 6, 2025. The exercise price for certain fully vested stock options was reset to $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover 48,072 options (from $24.65; expiring Aug 15, 2031), 28,700 (from $16.29; expiring Jun 20, 2032), 37,500 (from $12.69; expiring Jun 21, 2033), and 32,335 (from $13.87; expiring May 22, 2034). All other terms remain unchanged.
Exercising at the new price requires service through the Retention Period, which runs from Nov 6, 2025 until the earlier of the 12-month anniversary or a Corporate Transaction, with specified exceptions for death or Disability.
Day One Biopharmaceuticals (DAWN): Form 4 discloses option repricing by a director. On 11/06/2025, previously granted and fully vested stock options with exercise prices ranging from $12.69 to $16.29 were canceled and replaced at a new exercise price of $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover multiple tranches with original expirations unchanged (ranging from 05/25/2031 to 05/22/2034). Exercising at the new price requires service through the “Retention Period,” which ends on the earlier of 12 months from the effective date or a Corporate Transaction, with specified exceptions. The transactions were exempt under Rule 16b-6(d) and Rule 16b-3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 showing an option repricing for its COO and CFO. On November 6, 2025, multiple stock option grants held by the reporting person were repriced to an exercise price of $8.99 if lower than the original price, following a Board approval on October 7, 2025.
The filing lists prior grants adjusted from higher strikes, including 497,667 underlying shares previously at $16 (fully vested), 151,000 at $14.26, 116,000 at $23.41, 162,000 at $14.44, and 162,000 at $11.87. The revised entries show corresponding grants at $8.99 with the same underlying share counts. Vesting terms remain unchanged, such as 2.0833% monthly with full vest by January 18, 2026, and multiple 1/48th monthly schedules starting on specified dates.
To exercise at the new price, continued service is required through the “Retention Period,” which runs from the effective date until the earlier of 12 months or a Corporate Transaction, with an exception for death or Disability under the plan.
Day One Biopharmaceuticals (DAWN) filed a Form 4 for its General Counsel & Secretary. On 11/06/2025, the officer was granted a stock option for 309,000 shares at an exercise price of $8.99, vesting 100% on November 6, 2026.
The filing also records an option repricing approved on October 7, 2025 and effective November 6, 2025: three existing options covering 90,000 shares each were canceled at prior exercise prices of $23.41, $14.44, and $11.87 and replaced with options at $8.99, keeping original expirations in 2033–2035 and monthly vesting schedules. To exercise at the new price, service through the Retention Period is required, which ends at the earlier of the 12‑month anniversary of the Effective Date or a Corporate Transaction.